Biochemical and histological impact of direct renin inhibition by aliskiren on myofibroblasts activation and differentiation in bleomycin induced pulmonary fibrosis in adult mice

Tissue and Cell

Volumn 47, Issue 4, 2015, Pages 373-381

  Asker, Samar A ^a   Mazroa, Shireen A ^a   Boshra, Vivian ^a   Hassan, Ahmed M ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Aliskiren; Myofibroblasts; Pulmonary fibrosis; TGF 1; SMA

Indexed keywords

ALISKIREN; ALPHA SMOOTH MUSCLE ACTIN; BLEOMYCIN; HYDROXYPROLINE; TRANSFORMING GROWTH FACTOR BETA1; ACTA2 PROTEIN, MOUSE; ACTIN; AMIDE; FUMARIC ACID DERIVATIVE; RENIN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; HISTOLOGY; IMMUNOHISTOCHEMISTRY; LUNG FIBROSIS; LUNG PARENCHYMA; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; PLASMA RENIN ACTIVITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; METABOLISM; PATHOLOGY;

MUS;

ACTINS; AMIDES; ANIMALS; BLEOMYCIN; CELL DIFFERENTIATION; FUMARATES; MICE; MYOFIBROBLASTS; PULMONARY FIBROSIS; RENIN; RENIN-ANGIOTENSIN SYSTEM; TRANSFORMING GROWTH FACTOR BETA;

EID: 84938955152     PISSN: 00408166     EISSN: 15323072     Source Type: Journal    
DOI: 10.1016/j.tice.2015.05.001     Document Type: Article

References (58)

1. Achar R.A., Silva T.C., Achar E., Martines R.B., Machado J.L. Use of insulin-like growth factor in the healing of open wounds in diabetic and non-diabetic rats. Acta Cir. Bras. 2014, 29(2):125-131.
2. Aihara Y., Yoshiji H., Noguchi R., Kaji K., Namisaki T., Shirai Y., Douhara A., Moriya K., Kawaratani H., Fukui H. Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model. Hepatol. Res. 2013, 43(11):1241-1250.
3. Alnajar A., Nordhoff C., Schied T., Chiquet-Ehrismann R., Loser K., Vogl T., Ludwig S., Wixler V. The LIM-only protein FHL2 attenuates lung inflammation during bleomycin-induced fibrosis. PLOS ONE 2013, 8(11):e81356.
4. Anscher M.S. Targeting the TGF-beta1 pathway to prevent normal tissue injury after cancer therapy. Oncologist 2010, 15(4):350-359.
5. Antoniu S.A. Targeting the angiotensin pathway in idiopathic pulmonary fibrosis. Expert Opin. Ther. Targets 2008, 12(12):1587-1590.
6. Anversa P., Kajstura J., Leri A., Loscalzo J. Tissue-specific adult stem cells in the human lung. Nat. Med. 2011, 17(9):1038-1039.
7. Atzori L., Chua F., Dunsmore S.E., Willis D., Barbarisi M., McAnulty R.J., Laurent G.J. Attenuation of bleomycin induced pulmonary fibrosis in mice using the heme oxygenase inhibitor Zn-deuteroporphyrin IX-2,4-bisethylene glycol. Thorax 2004, 59(3):217-223.
8. Baran C.P., Opalek J.M., McMaken S., Newland C.A., O'Brien J.M., Hunter M.G., Bringardner B.D., Monick M.M., Brigstock D.R., Stromberg P.C., Hunninghake G.W., Marsh C.B. Important roles for macrophage colony-stimulating factor, CC chemokine ligand 2, and mononuclear phagocytes in the pathogenesis of pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2007, 176(1):78-89.
9. Bonniaud P., Margetts P.J., Ask K., Flanders K., Gauldie J., Kolb M. TGF-β and Smad3 signaling link inflammation to chronic fibrogenesis. J. Immunol. 2005, 175(8):5390-5395.
10. Braber S., Verheijden K.A., Henricks P.A., Kraneveld A.D., Folkerts G. A comparison of fixation methods on lung morphology in a murine model of emphysema. Am. J. Physiol. Lung Cell. Mol. Physiol. 2010, 299(6):L843-L851.
11. Brown M.J. Aliskiren. Circulation 2008, 118(7):773-784.
12. Chen H., Brahmbhatt S., Gupta A., Sharma A. Duration of streptozotocin-induced diabetes differentially affects p38-mitogen-activated protein kinase (MAPK) phosphorylation in renal and vascular dysfunction. Cardiovasc. Diabetol. 2005, 4(1):3-11.
13. Cousin C., Bracquart D., Contrepas A., Nguyen G. Potential role of the (pro)renin receptor in cardiovascular and kidney diseases. J. Nephrol. 2010, 23:508-513.
14. Coward W.R., Saini G., Jenkins G. The pathogenesis of idiopathic pulmonary fibrosis. Ther. Adv. Respir. Dis. 2010, 4(6):367-388.
15. Desmouliere A., Chaponnier C., Gabbiani G. Tissue repair, contraction, and the myofibroblast. Wound Repair Regen. 2005, 13(1):7-12.
16. Du L., Sánchez C., Chen M., Edwards D.J., Shen B. The biosynthetic gene cluster for the antitumor drug bleomycin from Streptomyces verticillus ATCC15003 supporting functional interactions between nonribosomal peptide synthetases and a polyketide synthase. Chem. Biol. 2000, 7:623-642.
17. Furukawa M., Gohda T., Hagiwara S., Tanimoto M., Horikoshi S., Funabiki K., Tomino Y. Effect of the direct renin inhibitor aliskiren on urinary albumin excretion in spontaneous type 2 diabetic KK-A (y) mouse. Int. J. Nephrol. 2013, 2013:519130.
18. Graves P.R., Siddiqui F., Anscher M.S., Movsas B. Radiation pulmonary toxicity: from mechanisms to management. Semin. Radiat. Oncol. 2010, 20(3):201-207.
19. Hinz B. The myofibroblast in connective tissue repair and regeneration. Regenerative Medicine and Biomaterials for the Repair of Connective Tissues 2010, 39-82. Woodhead Publishing Ltd., Cambridge, UK. C.A.J. Ralphs (Ed.).
20. Huang H.C. Renin inhibition in portal hypertension: novel indication beyond cardiovascular diseases?. J. Chin. Med. Assoc. 2012, 75(11):547-548.
21. Huang J., Siragy H.M. Regulation of (pro)renin receptor expression by glucose-induced mitogen-activated protein kinase, nuclear factorkB, and activator protein-1 signaling pathways. Endocrinology 2010, 151(7):3317-3325.
22. Hulmes D.J. Building collagen molecules, fibrils, and suprafibrillar structures. J. Struct. Biol. 2002, 137(1-2):2-10.
23. Ji W.J., Ma Y.Q., Zhou X., Zhang Y.D., Lu R.Y., Guo Z.Z., Sun H.Y., Hu D.C., Yang G.H., Li Y.M., Wei L.Q. Spironolactone attenuates bleomycin-induced pulmonary injury partially via modulating mononuclear phagocyte phenotype switching in circulating and alveolar compartments. PLOS ONE 2013, 8(11):e81090.
24. Kalluri R., Neilson E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Invest. 2003, 112(12):1776-1784.
25. Ke C.Y., Lee C.C., Lee C.J., Subeq Y.M., Lee R.P., Hsu B.G. Aliskiren ameliorates chlorhexidine digluconate-induced peritoneal fibrosis in rats. Eur. J. Clin. Invest. 2010, 40(4):301-309.
26. Li C., Hu W., Han J., Shen L., Yue S., Feng D., Luo Z. Clara cells ablation increases Ki67 immunoexpression and histological grade in bleomycin lung. Regul. Pept. 2006, 135:141. [abstract].
27. Liu W., Wan J., Han J.Z., Li C., Feng D.D., Yue S.J., Huang Y.H., Chen Y., Cheng Q.M., Li Y., Luo Z.Q. Antiflammin-1 attenuates bleomycin-induced pulmonary fibrosis in mice. Respir. Res. 2013, 14:101.
28. Liu X., Qian L., Nan H., Cui M., Hao X., Du Y. Function of the transforming growth factor-β1/c-Jun N-terminal kinase signaling pathway in the action of thalidomide on a rat model of pulmonary fibrosis. Exp. Ther. Med. 2014, 7(3):669-674.
29. Lizakowski S., Tylicki L., Renke M., Rutkowski P., Heleniak Z., Sławińska-Morawska M., Aleksandrowicz-Wrona E., Małgorzewicz S., Rutkowski B. Aliskiren and perindopril reduce the levels of transforming growth factor-β in patients with non-diabetic kidney disease. Am. J. Hypertens. 2012, 25(6):636-639.
30. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin-phenol reagent. J. Biol. Chem. 1951, 193(1):265-275.
31. Lu H., Rateri D.L., Feldman D.L., Jr R.J., Fukamizu A., Ishida J., Oesterling E.G., Cassis L.A., Daugherty A. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J. Clin. Invest. 2008, 118:984-993.
32. Marshall R.P., Gohlke P., Chambers R.C., Howell D.C., Bottoms S.E., Unger T., McAnulty R.J., Laurent G.J. Angiotensin II and the fibroproliferative response to acute lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 286:L156-L164.
33. Meng G.Z., Zhang H.Y., Bu H., Zhang X.L., Pang Z.G., Ke Q., Liu X., Yang G. Myofibroblastic sarcomas: a clinicopathological study of 20 cases. Chin. Med. J. (Engl.) 2007, 120(5):363-369.
34. Montes E., Ruiz V., Checa M., Maldonado V., Melendez-Zajgla J., Montaño M., Ordoñez-Razo R., Cisneros J., García-de-Alba C., Pardo A., Selman M. Renin is an angiotensin-independent profibrotic mediator: role in pulmonary fibrosis. Eur. Respir. J. 2012, 39(1):141-148.
35. Mouratis M.A., Aidinis V. Modeling pulmonary fibrosis with bleomycin. Curr. Opin. Pulm. Med. 2011, 17:355-361.
36. Papp M., Li X., Zhuang J., Wang R., Uhal B.D. Angiotensin receptor subtype AT1 mediates alveolar epithelial cell apoptosis in response to ANG II. Am. J. Physiol. Lung Cell. Mol. Physiol. 2002, 282(4):L713-L718.
37. Pardo A., Selman M. Idiopathic pulmonary fibrosis: new insights in its pathogenesis. Int. J. Biochem. Cell Biol. 2002, 34(12):1534-1538.
38. Peng R., Sridhar S., Tyagi G., Phillips J.E., Garrido R., Harris P., Burns L., Renteria L., Woods J., Chen L., Allard J., Ravindran P., Bitter H., Liang Z., Hogaboam C.M., Kitson C., Budd D.C., Fine J.S., Bauer C.M., Stevenson C.S. Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease. PLOS ONE 2013, 8(4):e59348.
39. Phan S.H. The myofibroblast in pulmonary fibrosis. Chest 2002, 122(6):286S-289S.
40. Popova A.P., Bentley J.K., Anyanwu A.C., Richardson M.N., Linn M.J., Lei J., Wong E.J., Goldsmith A.M., Pryhuber G.S., Hershenson M.B. Glycogen synthase kinase-3β/β-catenin signaling regulates neonatal lung mesenchymal stromal cell myofibroblastic differentiation. Am. J. Physiol. Lung Cell. Mol. Physiol. 2012, 303(5):L439-L448.
41. Rafii R., Juarez M.M., Albertson T.E., Chan A.L. A review of current and novel therapies for idiopathic pulmonary fibrosis. J. Thorac Dis. 2013, 5(1):48-73.
42. Reinert T., Baldotto C., Nunes F., Scheliga A. Bleomycin-induced lung injury. J. Cancer Res. 2013, 480608.
43. Selman M., King T.E., Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med. 2001, 134(2):136-151.
44. Suarez C.J., Dintzis S.M., Frevert C.W. Respiratory. Comparative Anatomy and Histology. A Mouse and Human Atlas 2012, 121-134. Academic Press, Elsevier Inc., United States. first ed. P.M. Treuting, S.M. Dintzis, K.S. Montine, C.W. Frevert, D. Liggitt (Eds.).
45. Sueblinvong V., Neveu W.A., Neujahr D.C., Mills S.T., Rojas M., Roman J., Guidot D.M. Aging promotes pro-fibrotic matrix production and increases fibrocyte recruitment during acute lung injury. Adv. Biosci. Biotechnol. 2014, 5(1):19-30.
46. Suvarna K., Layton C., Bancroft J. Theory and Practice of Histological Techniques 2013, 173-214. Churchill Livingstone of Elsevier, Philadelphia, USA. seventh ed.
47. Tang N., Zhao Y., Feng R., Liu Y., Wang S., Wei W., Ding Q., An M.S., Wen J., Li L. Lysophosphatidic acid accelerates lung fibrosis by inducing differentiation of mesenchymal stem cells into myofibroblasts. J. Cell. Mol. Med. 2014, 18(1):156-169.
48. Thuy le T.T., Morita T., Yoshida K., Wakasa K., Iizuka M., Ogawa T., Mori M., Sekiya Y., Momen S., Motoyama H., Ikeda K., Yoshizato K., Kawada N. Promotion of liver and lung tumorigenesis in DEN-treated cytoglobin-deficient mice. Am. J. Pathol. 2011, 179(2):1050-1060.
49. Valencia J.C., Pacheco-Rodriguez G., Carmona A.K., Xavier J., Bruneval P., Riemenschneider W.K., Ikeda Y., Yu Z.X., Ferrans V.J., Moss J. Tissue-specific renin-angiotensin system in pulmonary lymphangioleiomyomatosis. Am. J. Respir. Cell Mol. Biol. 2006, 35(1):40-47.
50. Veerappan A., O'Connor N.J., Brazin J., Reid A.C., Jung A., McGee D., Summers B., Branch-Elliman D., Stiles B., Worgall S., Kaner R.J., Silver R.B. Mast cells: a pivotal role in pulmonary fibrosis. DNA Cell Biol. 2013, 32(4):206-218.
51. Wang H., Long X.B., Cao P.P., Wang N., Liu Y., Cui Y.H., Huang S.K., Liu Z. Clara cell 10-kD protein suppresses chitinase 3-like 1 expression associated with eosinophilic chronic rhinosinusitis. Am. J. Respir. Crit. Care Med. 2010, 181(9):908-916.
52. Weber J., Tiriveedhi V., Takenaka M., Lu W., Hachem R., Trulock E., Patterson G.A., Mohanakumar T. Inhibition of renin angiotensin aldosterone system causes abrogation of obliterative airways disease through inhibition of tumor necrosis factor-α-dependant interleukin-17. J. Heart Lung Transplant. 2012, 31(4):419-426.
53. Woessner J.F. The determination of hydroxyproline in tissue and protein samples containing small proportions of this amino acid. Arch. Biochem. Biophys. 1961, 93:440-447.
54. Wu W.P., Chang C.H., Chiu Y.T., Ku C.L., Wen M.C., Shu K.H., Wu M.J. A reduction of unilateral ureteral obstruction-induced renal fibrosis by a therapy combining valsartan with aliskiren. Am. J. Physiol. Renal Physiol. 2010, 299(5):F929-F941.
55. Wynn T.A. Integrating mechanisms of pulmonary fibrosis. J. Exp. Med. 2011, 208(4):1339-1350.
56. Yamamoto E., Kataoka K., Dong Y.F., Nakamura T., Fukuda M., Tokutomi Y., Matsuba S., Nako H., Nakagata N., Kaneko T., Ogawa H. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice. Hypertension 2009, 54(3):633-638.
57. Zhi H., Luptak I., Alreja G., Shi J., Guan J., Metes-Kosik N., Joseph J. Effects of direct renin inhibition on myocardial fibrosis and cardiac fibroblast function. PLOS ONE 2013, 8(12):e81612.
58. Zhou Y., Schneider D.J., Morschl E., Song L., Pedroza M., Karmouty-Quintana H., Le T., Sun C.X., Blackburn M.R. Distinct roles for the A2B adenosine receptor in acute and chronic stages of bleomycin-induced lung injury. J. Immunol. 2011, 186(2):1097-1106.